Armie Margaret Lee is a reporter covering private equity. Previously, she was at InvestmentWires, an online media company that focuses on the mutual fund and 401(k) industries. She has also covered real estate and banking for Miami Today and technology for Manila Times in the Philippines.

Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
France-based firm said its Phase 2 study of eryaspase (Graspa) in acute myeloid leukemia did not achieve its primary endpoint of overall survival.
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.
Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.
The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.
The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

Columnist Conversations

SPX-Cash The first short term support @ 2764.41 and holding remains short term bullish. I would still look to...
I caught up with Tyson Foods (TSN) CEO Tom Hayes for an interview on TheStreet that hit on Sunday. Hayes is b...
Gold prices have taken a dive in the wake of the Fed meeting. Interesting move considering how concerned Fed c...


News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.